Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Nigel H RussellCharlotte Wilhelm-BenartziJad OthmanRichard DilonStephen KnapperLeona M BattenJoanna CanhamEmily L HinsonSophie BetteridgeUlrik Malthe OvergaardAmanda GilkesNicola PotterPriyanka MehtaPanagiotis KottaridisJamie CavenaghClaire HemmawayClaire ArnoldSylvie D FreemanMike Dennisnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
mutations had substantial improvements in OS. By contrast, in patients with core binding factor AML, outcomes were excellent with DA + GO with no FLAG-Ida benefit.